Loading…

Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections

Humoral and cellular immune responses are known to be crucial for patients to recover from COVID-19 and to protect them against SARS-CoV-2 reinfection once infected or vaccinated. This study aimed to investigate humoral and T cell responses to SARS-CoV-2 vaccination in patients with autoimmune disea...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-04, Vol.14, p.1146841-1146841
Main Authors: Egri, Natalia, Calderón, Hugo, Martinez, Robert, Vazquez, Mario, Gómez-Caverzaschi, Verónica, Pascal, Mariona, Araújo, Olga, Juan, Manel, González-Navarro, Europa Azucena, Hernández-Rodríguez, José
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c469t-e1ca01617ea8ca91fc7689686c41ba1f62dca6efdca8e6cf287cbd356c3f791f3
cites cdi_FETCH-LOGICAL-c469t-e1ca01617ea8ca91fc7689686c41ba1f62dca6efdca8e6cf287cbd356c3f791f3
container_end_page 1146841
container_issue
container_start_page 1146841
container_title Frontiers in immunology
container_volume 14
creator Egri, Natalia
Calderón, Hugo
Martinez, Robert
Vazquez, Mario
Gómez-Caverzaschi, Verónica
Pascal, Mariona
Araújo, Olga
Juan, Manel
González-Navarro, Europa Azucena
Hernández-Rodríguez, José
description Humoral and cellular immune responses are known to be crucial for patients to recover from COVID-19 and to protect them against SARS-CoV-2 reinfection once infected or vaccinated. This study aimed to investigate humoral and T cell responses to SARS-CoV-2 vaccination in patients with autoimmune diseases after the second and third vaccine doses while on rituximab and their potential protective role against reinfection. Ten COVID-19-naïve patients were included. Three time points were used for monitoring cellular and humoral responses: pre-vaccine to exclude virus exposure (time point 1) and post-second and post-third vaccine (time points 2 and 3). Specific IgG antibodies were monitored by Luminex and T cells against SARS-CoV-2 spike-protein by ELISpot and CoVITEST. All episodes of symptomatic COVID-19 were recorded. Nine patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and one with an undifferentiated autoimmune disease were included. Nine patients received mRNA vaccines. The last rituximab infusion was administered for a mean (SD) of 15 (10) weeks before the first vaccine and six patients were CD19-B cell-depleted. After a mean (SD) of 19 (10) and 16 (2) days from the second and third vaccine dose, IgG anti-SARS-CoV-2 antibodies were detected in six (60%) and eight (80%) patients, respectively. All patients developed specific T cell responses by ELISpot and CoVITEST in time points 2 and 3. Previous B cell depletion correlated with anti-SARS-CoV-2 IgG levels. Nine (90%) patients developed mild COVID-19 after a median of 7 months of the third dose. Rituximab in patients with autoimmune diseases reduces humoral responses but does not avoid the development of T cell responses to SARS-CoV-2 vaccination, which remain present after a booster dose. A steady cellular immunity appears to be protective against subsequent reinfections.
doi_str_mv 10.3389/fimmu.2023.1146841
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_fba262c9ad9740ea9f5441e5d4ea4dfc</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_fba262c9ad9740ea9f5441e5d4ea4dfc</doaj_id><sourcerecordid>2813566061</sourcerecordid><originalsourceid>FETCH-LOGICAL-c469t-e1ca01617ea8ca91fc7689686c41ba1f62dca6efdca8e6cf287cbd356c3f791f3</originalsourceid><addsrcrecordid>eNpVks1u1DAUhSMEolXpC7BAXrLJEP-Mk7BB1ahApUpItLC17tjXM66SONhOYV6aZ8CZGaqpF7Zln3v82T5F8ZZWC86b9oN1fT8tWMX4glIhG0FfFOdUSlFyxsTLk_lZcRnjQ5WbaDnny9fFGa9pU1VtfV78XWHXTR0EAoMh26n3AToSMI5-iBgJ2ISBRNQ-b8-StHXBkLur73flyv8sGXkErd0AyeUC4gYy5ikOKZLfLm0JTMnPpAMS4yLC7JkCQkJzEASXpj-uh_VHEkfUzjpN7onOVGRf59Iu4_Tgsnvnhw0eSMcOdpmOjMEn1Mk9Igm-QwKbWZlOAQO6wc6aDPimeGWhi3h5HC-KH5-v71dfy9tvX25WV7elFrJNJVINFZW0Rmg0tNTqWjatbKQWdA3USmY0SLS5b1Bqy5parw1fSs1tneX8org5-BoPD2oM-YJhpzw4tV_wYaMgJKc7VHYNTDLdgmlrUSG0dikExaURCMJYnb0-HbzGad2j0flx8x89M32-M7it2vhHRStaC854dnh_dAj-14Qxqd7F-YlhQD9FxRqa2WUlaZayg1QHH2NA-3QOrdQcPLUPnpqDp47By0XvTgmfSv7HjP8DcGvdVQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2813566061</pqid></control><display><type>article</type><title>Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections</title><source>PubMed Central</source><creator>Egri, Natalia ; Calderón, Hugo ; Martinez, Robert ; Vazquez, Mario ; Gómez-Caverzaschi, Verónica ; Pascal, Mariona ; Araújo, Olga ; Juan, Manel ; González-Navarro, Europa Azucena ; Hernández-Rodríguez, José</creator><creatorcontrib>Egri, Natalia ; Calderón, Hugo ; Martinez, Robert ; Vazquez, Mario ; Gómez-Caverzaschi, Verónica ; Pascal, Mariona ; Araújo, Olga ; Juan, Manel ; González-Navarro, Europa Azucena ; Hernández-Rodríguez, José</creatorcontrib><description>Humoral and cellular immune responses are known to be crucial for patients to recover from COVID-19 and to protect them against SARS-CoV-2 reinfection once infected or vaccinated. This study aimed to investigate humoral and T cell responses to SARS-CoV-2 vaccination in patients with autoimmune diseases after the second and third vaccine doses while on rituximab and their potential protective role against reinfection. Ten COVID-19-naïve patients were included. Three time points were used for monitoring cellular and humoral responses: pre-vaccine to exclude virus exposure (time point 1) and post-second and post-third vaccine (time points 2 and 3). Specific IgG antibodies were monitored by Luminex and T cells against SARS-CoV-2 spike-protein by ELISpot and CoVITEST. All episodes of symptomatic COVID-19 were recorded. Nine patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and one with an undifferentiated autoimmune disease were included. Nine patients received mRNA vaccines. The last rituximab infusion was administered for a mean (SD) of 15 (10) weeks before the first vaccine and six patients were CD19-B cell-depleted. After a mean (SD) of 19 (10) and 16 (2) days from the second and third vaccine dose, IgG anti-SARS-CoV-2 antibodies were detected in six (60%) and eight (80%) patients, respectively. All patients developed specific T cell responses by ELISpot and CoVITEST in time points 2 and 3. Previous B cell depletion correlated with anti-SARS-CoV-2 IgG levels. Nine (90%) patients developed mild COVID-19 after a median of 7 months of the third dose. Rituximab in patients with autoimmune diseases reduces humoral responses but does not avoid the development of T cell responses to SARS-CoV-2 vaccination, which remain present after a booster dose. A steady cellular immunity appears to be protective against subsequent reinfections.</description><identifier>ISSN: 1664-3224</identifier><identifier>EISSN: 1664-3224</identifier><identifier>DOI: 10.3389/fimmu.2023.1146841</identifier><identifier>PMID: 37180097</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>anti CD-20 ; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ; Antibodies, Viral ; Autoimmune Diseases - drug therapy ; cellular response ; COVID - 19 ; COVID-19 Vaccines ; Humans ; humoral response ; Immunoglobulin G ; Immunology ; Reinfection ; rituximab ; Rituximab - therapeutic use ; SARS-CoV-2 ; SARS-CoV-2 vaccines ; T-Lymphocytes ; Vaccination</subject><ispartof>Frontiers in immunology, 2023-04, Vol.14, p.1146841-1146841</ispartof><rights>Copyright © 2023 Egri, Calderón, Martinez, Vazquez, Gómez-Caverzaschi, Pascal, Araújo, Juan, González-Navarro and Hernández-Rodríguez.</rights><rights>Copyright © 2023 Egri, Calderón, Martinez, Vazquez, Gómez-Caverzaschi, Pascal, Araújo, Juan, González-Navarro and Hernández-Rodríguez 2023 Egri, Calderón, Martinez, Vazquez, Gómez-Caverzaschi, Pascal, Araújo, Juan, González-Navarro and Hernández-Rodríguez</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c469t-e1ca01617ea8ca91fc7689686c41ba1f62dca6efdca8e6cf287cbd356c3f791f3</citedby><cites>FETCH-LOGICAL-c469t-e1ca01617ea8ca91fc7689686c41ba1f62dca6efdca8e6cf287cbd356c3f791f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174323/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10174323/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37180097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Egri, Natalia</creatorcontrib><creatorcontrib>Calderón, Hugo</creatorcontrib><creatorcontrib>Martinez, Robert</creatorcontrib><creatorcontrib>Vazquez, Mario</creatorcontrib><creatorcontrib>Gómez-Caverzaschi, Verónica</creatorcontrib><creatorcontrib>Pascal, Mariona</creatorcontrib><creatorcontrib>Araújo, Olga</creatorcontrib><creatorcontrib>Juan, Manel</creatorcontrib><creatorcontrib>González-Navarro, Europa Azucena</creatorcontrib><creatorcontrib>Hernández-Rodríguez, José</creatorcontrib><title>Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections</title><title>Frontiers in immunology</title><addtitle>Front Immunol</addtitle><description>Humoral and cellular immune responses are known to be crucial for patients to recover from COVID-19 and to protect them against SARS-CoV-2 reinfection once infected or vaccinated. This study aimed to investigate humoral and T cell responses to SARS-CoV-2 vaccination in patients with autoimmune diseases after the second and third vaccine doses while on rituximab and their potential protective role against reinfection. Ten COVID-19-naïve patients were included. Three time points were used for monitoring cellular and humoral responses: pre-vaccine to exclude virus exposure (time point 1) and post-second and post-third vaccine (time points 2 and 3). Specific IgG antibodies were monitored by Luminex and T cells against SARS-CoV-2 spike-protein by ELISpot and CoVITEST. All episodes of symptomatic COVID-19 were recorded. Nine patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and one with an undifferentiated autoimmune disease were included. Nine patients received mRNA vaccines. The last rituximab infusion was administered for a mean (SD) of 15 (10) weeks before the first vaccine and six patients were CD19-B cell-depleted. After a mean (SD) of 19 (10) and 16 (2) days from the second and third vaccine dose, IgG anti-SARS-CoV-2 antibodies were detected in six (60%) and eight (80%) patients, respectively. All patients developed specific T cell responses by ELISpot and CoVITEST in time points 2 and 3. Previous B cell depletion correlated with anti-SARS-CoV-2 IgG levels. Nine (90%) patients developed mild COVID-19 after a median of 7 months of the third dose. Rituximab in patients with autoimmune diseases reduces humoral responses but does not avoid the development of T cell responses to SARS-CoV-2 vaccination, which remain present after a booster dose. A steady cellular immunity appears to be protective against subsequent reinfections.</description><subject>anti CD-20</subject><subject>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</subject><subject>Antibodies, Viral</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>cellular response</subject><subject>COVID - 19</subject><subject>COVID-19 Vaccines</subject><subject>Humans</subject><subject>humoral response</subject><subject>Immunoglobulin G</subject><subject>Immunology</subject><subject>Reinfection</subject><subject>rituximab</subject><subject>Rituximab - therapeutic use</subject><subject>SARS-CoV-2</subject><subject>SARS-CoV-2 vaccines</subject><subject>T-Lymphocytes</subject><subject>Vaccination</subject><issn>1664-3224</issn><issn>1664-3224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVks1u1DAUhSMEolXpC7BAXrLJEP-Mk7BB1ahApUpItLC17tjXM66SONhOYV6aZ8CZGaqpF7Zln3v82T5F8ZZWC86b9oN1fT8tWMX4glIhG0FfFOdUSlFyxsTLk_lZcRnjQ5WbaDnny9fFGa9pU1VtfV78XWHXTR0EAoMh26n3AToSMI5-iBgJ2ISBRNQ-b8-StHXBkLur73flyv8sGXkErd0AyeUC4gYy5ikOKZLfLm0JTMnPpAMS4yLC7JkCQkJzEASXpj-uh_VHEkfUzjpN7onOVGRf59Iu4_Tgsnvnhw0eSMcOdpmOjMEn1Mk9Igm-QwKbWZlOAQO6wc6aDPimeGWhi3h5HC-KH5-v71dfy9tvX25WV7elFrJNJVINFZW0Rmg0tNTqWjatbKQWdA3USmY0SLS5b1Bqy5parw1fSs1tneX8org5-BoPD2oM-YJhpzw4tV_wYaMgJKc7VHYNTDLdgmlrUSG0dikExaURCMJYnb0-HbzGad2j0flx8x89M32-M7it2vhHRStaC854dnh_dAj-14Qxqd7F-YlhQD9FxRqa2WUlaZayg1QHH2NA-3QOrdQcPLUPnpqDp47By0XvTgmfSv7HjP8DcGvdVQ</recordid><startdate>20230427</startdate><enddate>20230427</enddate><creator>Egri, Natalia</creator><creator>Calderón, Hugo</creator><creator>Martinez, Robert</creator><creator>Vazquez, Mario</creator><creator>Gómez-Caverzaschi, Verónica</creator><creator>Pascal, Mariona</creator><creator>Araújo, Olga</creator><creator>Juan, Manel</creator><creator>González-Navarro, Europa Azucena</creator><creator>Hernández-Rodríguez, José</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20230427</creationdate><title>Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections</title><author>Egri, Natalia ; Calderón, Hugo ; Martinez, Robert ; Vazquez, Mario ; Gómez-Caverzaschi, Verónica ; Pascal, Mariona ; Araújo, Olga ; Juan, Manel ; González-Navarro, Europa Azucena ; Hernández-Rodríguez, José</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c469t-e1ca01617ea8ca91fc7689686c41ba1f62dca6efdca8e6cf287cbd356c3f791f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>anti CD-20</topic><topic>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</topic><topic>Antibodies, Viral</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>cellular response</topic><topic>COVID - 19</topic><topic>COVID-19 Vaccines</topic><topic>Humans</topic><topic>humoral response</topic><topic>Immunoglobulin G</topic><topic>Immunology</topic><topic>Reinfection</topic><topic>rituximab</topic><topic>Rituximab - therapeutic use</topic><topic>SARS-CoV-2</topic><topic>SARS-CoV-2 vaccines</topic><topic>T-Lymphocytes</topic><topic>Vaccination</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Egri, Natalia</creatorcontrib><creatorcontrib>Calderón, Hugo</creatorcontrib><creatorcontrib>Martinez, Robert</creatorcontrib><creatorcontrib>Vazquez, Mario</creatorcontrib><creatorcontrib>Gómez-Caverzaschi, Verónica</creatorcontrib><creatorcontrib>Pascal, Mariona</creatorcontrib><creatorcontrib>Araújo, Olga</creatorcontrib><creatorcontrib>Juan, Manel</creatorcontrib><creatorcontrib>González-Navarro, Europa Azucena</creatorcontrib><creatorcontrib>Hernández-Rodríguez, José</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Egri, Natalia</au><au>Calderón, Hugo</au><au>Martinez, Robert</au><au>Vazquez, Mario</au><au>Gómez-Caverzaschi, Verónica</au><au>Pascal, Mariona</au><au>Araújo, Olga</au><au>Juan, Manel</au><au>González-Navarro, Europa Azucena</au><au>Hernández-Rodríguez, José</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections</atitle><jtitle>Frontiers in immunology</jtitle><addtitle>Front Immunol</addtitle><date>2023-04-27</date><risdate>2023</risdate><volume>14</volume><spage>1146841</spage><epage>1146841</epage><pages>1146841-1146841</pages><issn>1664-3224</issn><eissn>1664-3224</eissn><abstract>Humoral and cellular immune responses are known to be crucial for patients to recover from COVID-19 and to protect them against SARS-CoV-2 reinfection once infected or vaccinated. This study aimed to investigate humoral and T cell responses to SARS-CoV-2 vaccination in patients with autoimmune diseases after the second and third vaccine doses while on rituximab and their potential protective role against reinfection. Ten COVID-19-naïve patients were included. Three time points were used for monitoring cellular and humoral responses: pre-vaccine to exclude virus exposure (time point 1) and post-second and post-third vaccine (time points 2 and 3). Specific IgG antibodies were monitored by Luminex and T cells against SARS-CoV-2 spike-protein by ELISpot and CoVITEST. All episodes of symptomatic COVID-19 were recorded. Nine patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis and one with an undifferentiated autoimmune disease were included. Nine patients received mRNA vaccines. The last rituximab infusion was administered for a mean (SD) of 15 (10) weeks before the first vaccine and six patients were CD19-B cell-depleted. After a mean (SD) of 19 (10) and 16 (2) days from the second and third vaccine dose, IgG anti-SARS-CoV-2 antibodies were detected in six (60%) and eight (80%) patients, respectively. All patients developed specific T cell responses by ELISpot and CoVITEST in time points 2 and 3. Previous B cell depletion correlated with anti-SARS-CoV-2 IgG levels. Nine (90%) patients developed mild COVID-19 after a median of 7 months of the third dose. Rituximab in patients with autoimmune diseases reduces humoral responses but does not avoid the development of T cell responses to SARS-CoV-2 vaccination, which remain present after a booster dose. A steady cellular immunity appears to be protective against subsequent reinfections.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>37180097</pmid><doi>10.3389/fimmu.2023.1146841</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-3224
ispartof Frontiers in immunology, 2023-04, Vol.14, p.1146841-1146841
issn 1664-3224
1664-3224
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_fba262c9ad9740ea9f5441e5d4ea4dfc
source PubMed Central
subjects anti CD-20
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Antibodies, Viral
Autoimmune Diseases - drug therapy
cellular response
COVID - 19
COVID-19 Vaccines
Humans
humoral response
Immunoglobulin G
Immunology
Reinfection
rituximab
Rituximab - therapeutic use
SARS-CoV-2
SARS-CoV-2 vaccines
T-Lymphocytes
Vaccination
title Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T23%3A35%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cellular%20and%20humoral%20responses%20after%20second%20and%20third%20SARS-CoV-2%20vaccinations%20in%20patients%20with%20autoimmune%20diseases%20treated%20with%20rituximab:%20specific%20T%20cell%20immunity%20remains%20longer%20and%20plays%20a%20protective%20role%20against%20SARS-CoV-2%20reinfections&rft.jtitle=Frontiers%20in%20immunology&rft.au=Egri,%20Natalia&rft.date=2023-04-27&rft.volume=14&rft.spage=1146841&rft.epage=1146841&rft.pages=1146841-1146841&rft.issn=1664-3224&rft.eissn=1664-3224&rft_id=info:doi/10.3389/fimmu.2023.1146841&rft_dat=%3Cproquest_doaj_%3E2813566061%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c469t-e1ca01617ea8ca91fc7689686c41ba1f62dca6efdca8e6cf287cbd356c3f791f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2813566061&rft_id=info:pmid/37180097&rfr_iscdi=true